The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved two new formulations of the medicine cabotegravir to help prevent sexually transmitted HIV-1 infection. 3 May 2024
Amgen has reported better-than-expected first quarter results, with simultaneous news from its obesity pipeline lifting the firm’s stock price by almost 15%. 3 May 2024
Philadelphia, USA-based Reunion Neuroscience, a company developing psychedelics for the treatment of mental health conditions, has announced the closing of a $103 million Series A financing. 3 May 2024
New Jersey, USA-based PDS Biotechnology today announced the appointment of Stephan Toutain, as chief operating officer (COO), effective as of May 1, 2024. 2 May 2024
The COVID-19 pandemic has underscored the vulnerabilities inherent in global supply chains, particularly those predicated on single-country reliance. 2 May 2024
Californian firm Daré Bioscience has completed a royalty monetization deal with XOMA, a company providing an alternative mechanism for biotechs to raise capital. 2 May 2024
San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second collaboration with Japanese drug major Astellas Pharma. 2 May 2024
Sanofi’s Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalizations by 82% in infants under six months of age, compared to babies who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. 2 May 2024
Danish diabetes giant Novo Nordisk today reported financial results for the first quarter of 2024, noting that sales increased by 22% in Danish kroner and by 24% at constant exchange rates to 65.3 billion kroner ($9.35 billion). 2 May 2024
New Zealand-based AFT Pharmaceuticals has announced the licensing of Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for Brazil. 2 May 2024